Overview

Epcoritamab in Previously Treated WM

Status:
RECRUITING

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study is: -Epcoritamab (a type of antibody)

Phase:

PHASE2

Details

Lead Sponsor:

Gottfried von Keudell, MD PhD

Collaborator:

Genmab